$MTEM
Molecular Templates, Inc.

2022 Q4 Form 10-Q Financial Statement

#000156459022037419 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $2.611M $4.240M $2.379M
YoY Change -85.47% 78.23% -44.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.080M $5.934M $9.027M
YoY Change -23.31% -34.26% 19.56%
% of Gross Profit
Research & Development $17.59M $21.97M $22.88M
YoY Change -9.03% -3.97% 16.61%
% of Gross Profit
Depreciation & Amortization $1.819M $2.000M $1.700M
YoY Change 0.94% 17.65% 41.67%
% of Gross Profit
Operating Expenses $23.67M $27.91M $31.91M
YoY Change -13.19% -12.54% 17.44%
Operating Profit -$23.67M -$29.53M
YoY Change -19.85% 29.11%
Interest Expense -$963.0K $307.0K $175.0K
YoY Change 2.23% 75.43% 4.79%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$22.02M -$24.61M -$30.39M
YoY Change 115.0% -19.0% 30.84%
Income Tax $27.00K $26.00K $0.00
% Of Pretax Income
Net Earnings -$22.05M -$24.64M -$30.39M
YoY Change 115.26% -18.92% 30.84%
Net Earnings / Revenue -844.47% -581.08% -1277.3%
Basic Earnings Per Share -$0.44 -$0.54
Diluted Earnings Per Share -$0.39 -$0.44 -$540.9K
COMMON SHARES
Basic Shares Outstanding 56.35M 56.35M 56.17M
Diluted Shares Outstanding 56.35M 56.17M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $61.05M $79.45M $169.4M
YoY Change -57.32% -53.1% 45.76%
Cash & Equivalents $32.19M $22.28M $27.59M
Short-Term Investments $28.86M $57.17M $141.8M
Other Short-Term Assets $3.790M $4.011M $8.068M
YoY Change 202.23% -50.29% -15.96%
Inventory
Prepaid Expenses $3.459M $3.729M
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $68.30M $87.19M $177.4M
YoY Change -53.92% -50.87% 36.81%
LONG-TERM ASSETS
Property, Plant & Equipment $14.63M $16.35M $20.45M
YoY Change -24.22% -20.07% -2.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $6.013M
YoY Change -100.0% -100.0% 200.65%
Other Assets $3.486M $3.994M $5.019M
YoY Change -51.88% -20.42% -3.48%
Total Long-Term Assets $29.25M $31.46M $40.49M
YoY Change -33.74% -22.29% 1.98%
TOTAL ASSETS
Total Short-Term Assets $68.30M $87.19M $177.4M
Total Long-Term Assets $29.25M $31.46M $40.49M
Total Assets $97.55M $118.6M $217.9M
YoY Change -49.29% -45.56% 28.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $504.0K $1.085M $1.311M
YoY Change -68.73% -17.24% -49.58%
Accrued Expenses $8.823M $8.890M $11.31M
YoY Change -7.27% -21.36% -14.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $57.08M $50.22M $47.40M
YoY Change 22.31% 5.96% 17.32%
LONG-TERM LIABILITIES
Long-Term Debt $36.17M $35.94M $35.25M
YoY Change 1.91% 1.95% 138.18%
Other Long-Term Liabilities $1.295M $1.269M $63.18M
YoY Change -20.31% -97.99% 112.71%
Total Long-Term Liabilities $37.46M $37.21M $98.43M
YoY Change 0.93% -62.2% 121.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $57.08M $50.22M $47.40M
Total Long-Term Liabilities $37.46M $37.21M $98.43M
Total Liabilities $112.7M $114.5M $145.8M
YoY Change -11.07% -21.48% 71.76%
SHAREHOLDERS EQUITY
Retained Earnings -$444.8M -$422.7M
YoY Change 26.35%
Common Stock $429.7M $427.1M
YoY Change 2.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$15.13M $4.152M $72.11M
YoY Change
Total Liabilities & Shareholders Equity $97.55M $118.6M $217.9M
YoY Change -49.29% -45.56% 28.65%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$22.05M -$24.64M -$30.39M
YoY Change 115.26% -18.92% 30.84%
Depreciation, Depletion And Amortization $1.819M $2.000M $1.700M
YoY Change 0.94% 17.65% 41.67%
Cash From Operating Activities -$18.43M -$24.43M -$24.81M
YoY Change -17.94% -1.54% 25.18%
INVESTING ACTIVITIES
Capital Expenditures $312.0K -$986.0K -$1.323M
YoY Change -135.33% -25.47% 22.5%
Acquisitions
YoY Change
Other Investing Activities $28.66M $20.57M $9.780M
YoY Change 38.47% 110.29% -145.47%
Cash From Investing Activities $28.35M $19.58M $8.457M
YoY Change 43.06% 131.52% -137.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 9.000K 856.0K
YoY Change -100.0% -98.95% -98.24%
NET CHANGE
Cash From Operating Activities -18.43M -24.43M -24.81M
Cash From Investing Activities 28.35M 19.58M 8.457M
Cash From Financing Activities 0.000 9.000K 856.0K
Net Change In Cash 9.913M -4.838M -15.50M
YoY Change -479.81% -68.78% -349.55%
FREE CASH FLOW
Cash From Operating Activities -$18.43M -$24.43M -$24.81M
Capital Expenditures $312.0K -$986.0K -$1.323M
Free Cash Flow -$18.74M -$23.44M -$23.49M
YoY Change -13.13% -0.2% 25.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
17143000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
20733000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
563000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4011000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1254000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
148215000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
8986000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20120000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
27907000
us-gaap Operating Income Loss
OperatingIncomeLoss
-70773000
mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
3394000
mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
2301000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30387000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5934000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30387000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70669000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
59340000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1543000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
0
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-234000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1582000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3885000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2375000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28886000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24766000
mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
17143000
mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
20733000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12822000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M4D
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4243000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
87185000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M3D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M10D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y6M10D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M6D
CY2022Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
4240000
CY2021Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
2379000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21973000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22881000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64835000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65328000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9027000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26178000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
31908000
us-gaap Operating Expenses
OperatingExpenses
84955000
us-gaap Operating Expenses
OperatingExpenses
91506000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23667000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29529000
us-gaap Operating Income Loss
OperatingIncomeLoss
-67812000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
307000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
175000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
308000
CY2022Q3 mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
1252000
CY2021Q3 mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
1033000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24612000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30387000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-70643000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72766000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24638000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72766000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54958365
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56350858
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56350858
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56174644
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56174644
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56328664
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56328664
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54958365
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24638000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70669000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72766000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
103000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-179000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24535000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30396000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70848000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72784000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
26037000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
97402000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65662000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
4152000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
72105000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
4152000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
72105000
us-gaap Net Income Loss
NetIncomeLoss
-70669000
us-gaap Net Income Loss
NetIncomeLoss
-72766000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5564000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4828000
us-gaap Share Based Compensation
ShareBasedCompensation
9305000
us-gaap Share Based Compensation
ShareBasedCompensation
12822000
mtem Interest Accrued On Long Term Debt
InterestAccruedOnLongTermDebt
64000
mtem Interest Accrued On Long Term Debt
InterestAccruedOnLongTermDebt
137000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
747000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
497000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
98000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
100000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-29000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-356000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-188000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
724000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-818000
mtem Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-572000
mtem Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
504000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-572000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1048000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-694000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1635000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-472000
mtem Increase Decrease In Other Noncurrent Liabilities Related Parties
IncreaseDecreaseInOtherNoncurrentLiabilitiesRelatedParties
0
mtem Increase Decrease In Other Noncurrent Liabilities Related Parties
IncreaseDecreaseInOtherNoncurrentLiabilitiesRelatedParties
-11853000
mtem Increase Decreases In Collaboration Revenue
IncreaseDecreasesInCollaborationRevenue
-13356000
mtem Increase Decreases In Collaboration Revenue
IncreaseDecreasesInCollaborationRevenue
64990000
mtem Increase Decrease In Deferred Revenue Related Parties Current
IncreaseDecreaseInDeferredRevenueRelatedPartiesCurrent
0
mtem Increase Decrease In Deferred Revenue Related Parties Current
IncreaseDecreaseInDeferredRevenueRelatedPartiesCurrent
-3895000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70592000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7926000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2886000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3113000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
52132000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
184490000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
121990000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
105350000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
66972000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-82253000
mtem Payments Of Capital And Financing Lease Obligations
PaymentsOfCapitalAndFinancingLeaseObligations
0
mtem Payments Of Capital And Financing Lease Obligations
PaymentsOfCapitalAndFinancingLeaseObligations
1000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
19828000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
33000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
71145000
mtem Fees Paid On Loan Modification
FeesPaidOnLoanModification
298000
mtem Fees Paid On Loan Modification
FeesPaidOnLoanModification
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-265000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
92554000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28651000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31261000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22277000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27593000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2489000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3668000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24766000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31261000
us-gaap Interest Paid Net
InterestPaidNet
2471000
us-gaap Interest Paid Net
InterestPaidNet
1481000
mtem Fixed Asset Additions In Accounts Payable And Accrued Expenses
FixedAssetAdditionsInAccountsPayableAndAccruedExpenses
50000
mtem Fixed Asset Additions In Accounts Payable And Accrued Expenses
FixedAssetAdditionsInAccountsPayableAndAccruedExpenses
237000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-422700000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
79400000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2500000
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments, long term debt and accounts receivable.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s cash and cash equivalents are with two major financial institutions in the United States.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs an ongoing credit evaluation of its strategic partners’ financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. At September 30, 2022, the Company’s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within <span style="Background-color:#FFFFFF;color:#000000;">Bristol Myers Squibb Company (“Bristol Myers Squibb”). In past years, </span>the Company’s exposure to credit risk associated with non-payment were also affected principally by conditions or occurrences within<span style="Background-color:#FFFFFF;color:#000000;"> </span>Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd. (“Takeda”), and <span style="Background-color:#FFFFFF;color:#000000;">Vertex Pharmaceuticals Incorporated (“Vertex”)</span>. Takeda accounted for approximately <span>0%</span> of total revenues for the three months ended September 30, 2022 and 2021, respectively and approximately 15% and 63% of total revenues for the nine months ended September 30, 2022 and 2021. Vertex accounted for approximately 0% and 65% of total revenues for the three months ended September 30, 2022 and 2021, respectively and 0% and 19% of total revenues for the nine months ended September 30, 2022 and 2021. <span style="Background-color:#FFFFFF;color:#000000;">Bristol Myers Squibb</span> accounted for approximately 100% and 35% of total revenues for the three months ended September 30, 2022 and 2021, respectively and approximately 85% and 18% of total revenues for the nine months ended September 30, 2022 and 2021.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug or biologic candidates developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration (“FDA”) or international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s drug or biologic candidates will receive any of the required approvals or clearances. If the Company were to be denied approval or clearance or any such approval or clearance were to be delayed, it would have a material adverse impact on the Company.</p>
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2022Q3 mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
4240000
CY2021Q3 mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
2379000
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
78355000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
57168000
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
78355000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
152105000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
118061000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
8986000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
152105000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
78582000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
78355000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
78582000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
78355000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
143142000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
143119000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
152153000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
152105000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
9011000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
8986000
CY2022Q3 mtem Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
1061000
CY2021Q4 mtem Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
794000
CY2022Q3 mtem Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
830000
CY2021Q4 mtem Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
1134000
CY2022Q3 mtem Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
2691000
CY2021Q4 mtem Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
2153000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4254000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5388000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
54000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
46000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8890000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9515000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
35843000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33162000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19496000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13853000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16347000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19309000
CY2022Q3 us-gaap Depreciation
Depreciation
2000000.0
CY2021Q3 us-gaap Depreciation
Depreciation
1700000
us-gaap Depreciation
Depreciation
5700000
us-gaap Depreciation
Depreciation
4800000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
35900000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
35500000
CY2022Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P7Y
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
684000
us-gaap Operating Lease Cost
OperatingLeaseCost
1885000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
156000
us-gaap Variable Lease Cost
VariableLeaseCost
367000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
840000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2252000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11120000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1957000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12422000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
14379000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y9M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y7M24D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0809
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0702
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
682000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3122000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3164000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3121000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2563000
CY2022Q3 mtem Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
5507000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
18159000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3780000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
14379000
us-gaap Operating Lease Payments
OperatingLeasePayments
2518000
CY2022Q3 mtem Upfront Fees Unamortized Balance Included In Prepaid Asset
UpfrontFeesUnamortizedBalanceIncludedInPrepaidAsset
400000
CY2022Q3 us-gaap Contractual Obligation
ContractualObligation
48400000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2641000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9305000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
20100000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6697927
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.13
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13790000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2683818
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.84
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
320716
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.05
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1206556
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
11.46
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7854473
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.21
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
950000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2890789
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.22
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
46598
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2105531
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
9.58
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8593133
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.73
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10000.00
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
8593133
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.73
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
10000.00
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4605401
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1200000
mtem Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options1
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions1
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.90
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0

Files In Submission

Name View Source Status
0001564590-22-037419-index-headers.html Edgar Link pending
0001564590-22-037419-index.html Edgar Link pending
0001564590-22-037419.txt Edgar Link pending
0001564590-22-037419-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g2ix2votuild000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
mtem-10q_20220930.htm Edgar Link pending
mtem-20220930.xsd Edgar Link pending
mtem-ex101_59.htm Edgar Link pending
mtem-20220930_cal.xml Edgar Link unprocessable
mtem-20220930_def.xml Edgar Link unprocessable
mtem-20220930_pre.xml Edgar Link unprocessable
mtem-20220930_lab.xml Edgar Link unprocessable
mtem-10q_20220930_htm.xml Edgar Link completed
mtem-ex311_8.htm Edgar Link pending
mtem-ex312_6.htm Edgar Link pending
mtem-ex321_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable